Medtronic is to work with Qualcomm Life to develop a new generation of smaller, affordable continuous glucose monitors (CGMs) for people with Type 2 diabetes (as well as those with Type 1). Currently, CGM devices are mostly prescribed for people with Type 1 diabetes, while those with Type 2 are more likely to use discrete finger-prick glucometers. However, this new partnership aims to leverage Qualcomm’s expertise to develop CGMs that are smaller, easier to use, and more affordable than currently available CGMs — in the hopes of making the technology available to those with Type 2 diabetes. There are 20 times more people with Type 2 diabetes.
Qualcomm has worked with a number of major healthcare companies to develop device pilots over the last few years including pharma companies Roche, Novartis, and GSK while Medtronic has embarked on a number of partnerships within diabetes care, currently working with Samsung to optimize the viewing of CGM and pump data from its MiniMed Connect offering, and with IBM Watson to apply cognitive computing to data from Medtronic’s CareLink Connect system. As reported in Mobihealthnews.com
This news item first appeared in Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.
